U.S. CDC advisers back COVID-19 booster shots for those 65 and older, not for high-risk workers

(Reuters) -A U.S. Centers for Disease Control and Prevention (CDC) advisory panel on Thursday recommended a booster shot of the Pfizer and BioNTech COVID-19 vaccine for Americans aged 65 and older and some adults with underlying medical conditions that put them at risk of severe disease.

But the panel declined to recommend boosters for younger adults, including healthcare workers, who live or work in institutions with high risk of contracting COVID-19, which could narrow the scope of the U.S. Food and Drug Administration’s emergency use authorization here issued on Wednesday.

The guidelines voted on by the CDC’s Advisory Committee on Immunization Practices still need to be signed off on by agency Director Rochelle Walensky. The recommendations are not binding, and states and other jurisdictions could disregard them and use other approaches to administering the booster shots.

Still, the vote by the group, following the FDA’s authorization clears the way for a booster rollout to begin as soon as this week for millions of people who had their second dose of the Pfizer shot at least six months ago.

Beyond older Americans, the committee also recommended the shots for all adults over 50 with underlying conditions, as well as some 18- to 49-year-olds with those conditions, based on their individual risk profile. Those conditions include cancer, diabetes, certain heart conditions and chronic kidney disease and lung disorders.

The recommendations only cover people who received their second Pfizer/BioNTech shot at least six months earlier. The CDC said that group is currently about 26 million people, including 13 million age 65 or older.

The panel gave the thumbs down for now to additional doses for groups including healthcare workers, teachers and residents of homeless shelters and prisons, in part because of the difficulty of implementing such a proposal.

Panel member Lynn Bahta, who works with the Minnesota Department of Health, voted against that measure, which would have broadly increased availability. She said the data does not support boosters in that group yet. “The science shows that we have a really effective vaccine,” she said.

The committee said it could revisit the guidance later.

Last month, U.S. President Joe Biden and eight top health officials said they hoped to start a broad booster shot program this week, saying that emerging data showed immunity wanes over time.

Vaccine expert Dr. Paul Offit said he believed the CDC advisers were worried that recommending boosters based on employment would allow overly broad use, especially in younger people for whom the health benefits of a booster shot are still unclear.

“That was a hole that you could drive a truck through, that essentially what we were doing was basically what the (Biden) administration initially asked – to just have a vaccine for the general population, because obviously the pharmacists aren’t going to figure out whether you’re working in a grocery store or hospital,” he said.

More than 180 million people in the United States are fully vaccinated, or about 64% of the eligible population.

Pfizer – and some top U.S. health officials like Dr. Anthony Fauci – have argued that the extra round of shots are needed to address waning immunity. Fauci and others have also here they could help contain surging hospitalizations and deaths caused by the highly transmissible Delta variant of the coronavirus by cutting breakthrough infections of fully vaccinated people.

The recent wave of U.S. COVID-19 hospitalizations, primarily among the unvaccinated, may have peaked, although the nation was still recording some 1,500 COVID-19 deaths a day over the last week, according to CDC data.

Some countries, including Israel and the United Kingdom, have already begun COVID-19 booster campaigns. The United States authorized extra shots for people with compromised immune systems last month and around 2.3 million people have already received a third shot, according to the CDC.

Source: Read Full Article